AIM Company Profile

Below is the information we hold on the AIM company you have chosen to view. As a registered user, you can can view the Share Price, any public documents or presentations on the AIM company plus any additional details. Click on the share price ‘Block’ and you can view extended charting and share information. ‘Bookmark’ the company to your own portfolio, print off the page details and download as a ‘pdf’. You can also rate this AIM company by simply clicking the ‘star’ rating. If we hold news on this company, relevant articles will be displayed for you to view. Note: All share information is subject to a 15min. delay.

TRADE SHARES IN THIS AIM COMPANY

RENALYTIX AI

0.0
  1. Technology Hardware & Equipment
  2. » RENALYTIX AI
Share Price
Share Activity:
×
Key metrics
Market Cap
PE Ratio
PEG Ratio
EPS
Beta
Dividends
Dividend Rate
Dividend Yield
Ex Dividend Date
50 Days Moving Average
200 Days Moving Average
Key data
Symbol
Name
Bid
Ask
Last Price
Change
52 Week Low
52 Week High
Symbol Name Last Price Change % Change Day Low Day High

Click to View Charting

Key Company Info.
News:

Company Description:

 

Renalytix AI is a developer of artificial intelligence ("AI") decision support and clinical management tools for improving early diagnosis, continual monitoring and drug development for kidney disease. The Company was incorporated in March 2018 as a wholly-owned subsidiary of EKF Diagnostics Holdings plc ("EKF"), the AIM-quoted point-of-care diagnostics business. The Company's creation was the first step in EKF's announced strategy to spin-out certain biomarker and AI technology to facilitate its further development and commercialisation. RenalytixAI is currently working in collaboration with world-leading medical institutions to secure development and commercial launch of two artificial intelligence guided products, KidneyIntelX? and KidneyIntelX? APOL1, which the Company intends to submit for FDA review. Subject to funding, the Company is also expecting to develop further products throughout the kidney disease lifecycle, including tools to more accurately assess the type and amount of immunosuppression drugs needed by patients who have undergone kidney transplant surgery (FractalDx). The Company's main country of operation is the United States.

Active: Trading
EPIC:

RENX

List date: 16th November 2018 00:00
Contact Information
You must be logged in to see this info
Advisors
Nominated Advisor:

Singer Advisory LLP (together with its associates, "N+1 Singer")

Broker:

N+1 Singer

Listing Tags:

If this profile is about your AIM company, but the information is limited you can add to the information we hold. The company displayed HERE is a typical example of the type of information we can display about your company. Good promotion of your AIM listed company is critical for exposure to potential investors and liquidity in shares. Get in touch HERE if you would like to know more about how we can help promote your AIM listed company.